Veru (VERU) Earnings Dates, Call Summary & Reports

Compare

2,000 Followers

Earnings Data

Report Date

May 07, 2026

Before Open (Confirmed)

Period Ending

2026 (Q2)

Consensus EPS Forecast

-0.29

Last Year’s EPS

-0.5

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 2 Analysts Ratings

Earnings Call Summary

Q1 2026

Earnings Call Date:Feb 11, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call conveyed multiple substantive positives: a supportive FDA meeting clarifying development pathways, positive Phase 2b proof-of-concept data for Novosarm, an attractive BMD surrogate endpoint opportunity, a planned Phase 2b PLATO study with defined endpoints, and improved liquidity after a $23.4M financing that increased cash to ~$33M and materially improved working capital and operating expense trends. Offsetting risks include the company remaining unprofitable, reliance on cash through the interim analysis (creating near-term financing risk), conditional regulatory approval criteria if incremental weight loss is under 5%, nonrecurring prior-period gains, and long timelines to meaningful readouts (interim not expected until 2027). Overall, the highlights and strengthened balance sheet and regulatory clarity meaningfully outweigh the lowlights, but execution and further financing remain key risks.

Company Guidance

The company said the FDA provided two acceptable regulatory paths for Novosarm: either at least a 5% placebo‑corrected incremental weight‑loss difference at 52 weeks, or, if incremental weight loss is <5%, a statistically significant, clinically meaningful preservation/improvement in physical function (e.g., Stair Climb) could support approval; the FDA also confirmed Novosarm 3 mg as an acceptable dose. Veru plans a ~200‑patient Phase 2b PLATO in patients ≥65 years with BMI ≥35 initiating semaglutide, with a primary endpoint of percent change in total body weight at 68 weeks and an interim DEXA analysis of lean and fat mass at 34 weeks (interim anticipated in 2027); key secondaries include total fat mass, total lean mass, Stair Climb (loaded/unloaded, duplicate runs), total hip BMD by DEXA, patient‑reported function, HbA1c and insulin resistance. Context: prior Phase 2b quality study enrolled 168 older patients and ~1,000 patients have been assessed with StairClimb across Novosarm studies; GLP‑1s can cause up to 50% of weight loss to be lean mass, 88% of patients hit a GLP‑1 weight‑loss plateau at 1 year (Cervant1) with 62.6% still clinically obese, and SELECT (n>17,000) reported 4–5x more hip/pelvic fractures on semaglutide in females and patients ≥75 (relevant to FDA’s Dec 19, 2025 qualification of total hip BMD by DEXA as a surrogate in postmenopausal osteoporosis). Financially, Veru completed an Oct 31, 2025 offering (1.4M shares, pre‑funded warrants for up to 7.0M shares, Series A and B warrants for up to 8.4M shares each) raising net ≈$23.4M, had $33.0M cash and $29.7M net working capital as of Dec 31, 2025, used $6.2M cash in operations in the quarter, and expects cash to fund operations through the planned interim analysis.

Positive Phase 2b Proof-of-Concept Results

Completed a positive Phase 2b 'quality' clinical trial in 168 older patients showing Novosarm combined with a GLP-1 receptor agonist produced greater loss of fat mass while preserving lean mass and physical function, and reduced weight/fat regain after semaglutide discontinuation.

Regulatory Clarity from Successful FDA Meeting

September 2025 FDA meeting provided clear development pathways for Novosarm in combination with a GLP-1 receptor agonist: (1) ≥5% placebo-corrected incremental weight loss at 52 weeks or (2) <5% incremental weight loss but demonstration of clinically meaningful preservation/improvement in physical function. FDA also confirmed Novosarm 3 mg as an acceptable dose for development.

New Validated BMD Surrogate Endpoint Opportunity

FDA announcement (Dec 19, 2025) that total hip BMD by DEXA is a validated surrogate endpoint in postmenopausal osteoporosis is directly relevant; Novosarm has preclinical data showing anabolic and anti-resorptive effects on bone, enabling a potential BMD-based approval pathway in postmenopausal women on GLP-1 therapy.

PLATO Phase 2b Trial Initiation and Design

Planned double-blind, placebo-controlled Phase 2b PLATO study to enroll ~200 patients ≥65 years with BMI ≥35 initiating semaglutide; primary endpoint is percent change in total body weight at 68 weeks with an interim DEXA-based analysis at 34 weeks for lean/fat mass. Principal investigator named; study expected to begin this quarter.

Successful Capital Raise Strengthening Cash Position

Completed an underwritten public offering on Oct 31, 2025, raising net proceeds of approximately $23.4M (common stock, pre-funded warrants and Series A/B warrants).

Improved Liquidity and Working Capital

Cash, cash equivalents, and restricted cash increased to $33.0M from $15.8M as of Sep 30, 2025 (approximately +109%). Net working capital rose to $29.7M from $11.1M (approximately +168%). Management states cash is expected to fund operations through the PLATO interim analysis.

Operating Expense and Loss Improvements

R&D expenses decreased to $1.3M from $5.7M (≈77% decrease) due to wind-down of the prior Phase 2b study. General & administrative expenses declined to $4.1M from $5.2M (≈21% decrease). Net loss improved to $5.3M ($0.26 per diluted share) from $8.9M ($0.61) in the prior-year quarter (≈40% improvement). Operating cash used decreased to $6.2M from $11.3M (≈45% reduction).

Veru (VERU) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VERU Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 07, 2026	2026 (Q2)	-0.28 / -	-0.5	―	―	―
Feb 11, 2026	2026 (Q1)	-0.47 / -0.26	-0.6	56.67% (+0.34)	―
Dec 17, 2025	2025 (Q4)	-0.36 / 0.05	-0.6	108.33% (+0.65)	―
Aug 12, 2025	2025 (Q3)	-0.53 / -0.50	-0.7	28.57% (+0.20)	―
May 08, 2025	2025 (Q2)	-0.63 / -0.50	-0.7	28.57% (+0.20)	―
Feb 13, 2025	2025 (Q1)	-0.76 / -0.60	-0.8	25.00% (+0.20)	―
Aug 08, 2024	2024 (Q3)	-0.58 / -0.70	0.7	-200.00% (-1.40)	―
May 08, 2024	2024 (Q2)	-0.53 / -0.70	-4.8	85.42% (+4.10)
Feb 08, 2024	2024 (Q1)	-1.20 / -0.80	-4.6	82.61% (+3.80)	―
Dec 14, 2023	2023 (Q4)	-0.23 / -0.23	-0.51	54.90% (+0.28)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VERU Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 11, 2026	$2.31	$2.30	-0.43%
Dec 17, 2025	$2.44	$2.23	-8.61%
Aug 12, 2025	$3.59	$3.17	-11.70%
May 08, 2025	$5.01	$5.22	+4.19%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Veru (VERU) report earnings?

Veru (VERU) is schdueled to report earning on May 07, 2026, Before Open (Confirmed).

What is Veru (VERU) earnings time?

Veru (VERU) earnings time is at May 07, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VERU EPS forecast?

VERU EPS forecast for the fiscal quarter 2026 (Q2) is -0.29.